This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

kim.angel

/Kim Angel

About Kim Angel

This author has not yet filled in any details.
So far Kim Angel has created 44 blog entries.

Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids

NEW YORK and CLEVELAND, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the United States Patent and Trademark Office (USPTO) issued a patent covering next-generation adeno-associated virus (AAV) capsids generated using the University of North Carolina’s (UNC) AIMTM vector platform and that [...]

Hunter Syndrome “Listening Session” Feb 4, 2020

Dear Members, We are writing to invite you to participate in an important phone call to help inform staff of the U.S. Food and Drug Administration (FDA) about the patient and caregiver experience of living with Hunter Syndrome. This is part of a “Listening Session” being co-hosted by FDA’s Patient Affairs Staff (PAS) and the National [...]

Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA

Neurocognitive development of youngest patients preserved 12-18 months post treatment; development scores remain within range of unaffected children Robust and sustained biomarker improvement across all dose cohorts with 8 months to 2 years of follow up RMAT meeting anticipated for 2H2019 to discuss next steps NEW YORK and CLEVELAND, July 25, 2019 (GLOBE NEWSWIRE) -- Abeona [...]

Lysogene – Ongoing Phase 2/3 clinical trial for Sanfilippo syndrome Type A (MPS IIIA)

Ongoing Phase 2/3 clinical trial for Sanfilippo syndrome Type A (MPS IIIA) In October 2018, Lysogene, a company focused on pioneering gene therapies for CNS disorders, partnered with Sarepta Therapeutics to move forward on the AAVance MPS IIIA clinical trial. The Phase 2/3 gene therapy trial started in December 2018. AAVance is currently recruiting patients for [...]

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

Interim data expected in the second half of 2019 NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical [...]

Abeona PACE Update: Fast Track granted by FDA for ABO-101

Today Abeona Therapeutics announced that the FDA has granted Fast Track designation to ABO-101, the investigational gene therapy approach currently being investigated in children with MPS IIIB. The phase 1/2 clinical study, ABT-002, is currently enrolling in Spain and the US though we are working to activate additional study sites. This is an important designation by the [...]